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Molecular targets (MT) are intra-cellular structures, 
ranging from proteins to DNA and RNA that are 
potential entities for pharmacological action. With 
advancements in different sub-cellular domains 
viz. glycomics, lipidomics, proteomics, genomics, 
transcriptomics, metabolomics, etc it has made 
possible identification of specific target molecules 
that are either up-regulated or down-regulated 
during physiological processes and in various 
disordered / diseased states. 
MT can be visualized by means of molecular 
imaging which maps the functions at cellular and 
molecular level in contrast to conventional 
diagnostic imaging which render good details of 
physical structure [1]. Molecular imaging 
encompasses nuclear medicine, radio-
pharmacology and radio-pharmaceuticals which 
largely make use of small quantities of radio-active 
isotopes. These procedures are minimally 
invasive, safe and cause little pain [2]. These in-
vivo techniques make use of existing imaging 
modalities like magnetic resonance imaging (MRI), 
positron emission tomography (PET), etc coupled 
with biomarker probes which chemically interact 
with extra- and intra-cellular milieu bringing about 
a change in image according to the molecular 
alterations in the desired area. The images are 
captured in real-time with highly sophisticated 
microscopy and nanoscopy procedures like atomic 
force microscopy (AFM), total internal reflection 
fluorescence (TIRF) microscopy and stimulated 
emission depletion (STED) nanoscopy. Furthering 
the scope of molecular imaging was the 
development of mass-spectrometry based matrix-
assisted laser desorption/ionization (MALDI) 
technique which allows quantitative analysis [3]. 
Though small molecules and protein therapeutics 
are well established agents in current pharmaco-
therapeutics, their target range is limited to only 
one-tenth of the cell membrane surface or 
hydrophobic protein façade. With these short-
comings, research efforts are directed in 
discovering next generation therapeutic 
approaches. Firstly, exploration of entities that 
promote the active endosomal uptake and release 
of molecules which are not lipid soluble like 
polypeptides, proteins and nucleic acids. 
Secondly, identification of molecules that enters 
the cell by passive diffusion, facilitated diffusion or 
active transport so as to reach the intracellular 
molecular targets [4].  
The targets for the pharmacological agents can be 
categorized under 9 headings (Table 1). 
Biotherapeutics, production of therapeutic 
materials using biological means, encompass 
techniques like recombinant DNA technology, 
genetic engineering, etc. Noteworthy progress has 
been made in the field of cancer therapeutics with 
identification/development of molecules capable of 
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generating extra-cellular or intra-cellular death 
signals which plunges the malignant cells to 
undergo apoptosis. One approach is development 
of tumor targeting antibody fragments genetically 
fused to a cytotoxic protein payload called 
Targeted Protein Therapeutics (TPTs) [6]. Other 
approaches being worked on are intra-cellular 
antibodies (intrabodies) [7] and peptide aptamers 
[8]. These developments are taking the 
therapeutics way forward, albeit rather slowly. 
Despite the fact that in-vitro studies are promising, 
some of the challenges still elude their application 
in in-vivo or real situation and cause high attrition 
in drug discovery. Few critical elements in 
successful drug development and designing are 
adequate target exposure, bio-availability (both 
extra-cellular and intra-cellular) and ideal route of 
delivery. Recently, a technique was developed to 
quantify the intra-cellular concentration of drug and 
hence its availability to bind to molecular target 
which translates into pharmacological effect [8]. 
Earlier, the physiological basis of medicine was to 
target the cells, but of late the efforts are directed 
towards targeting sub-cellular structures. So, this 
is what is meant by ‘Target with-in target: Aiming 
to break therapeutic mediocrity’. 
Table 1: Categories of pharmaco-therapeutic targets [5] 
Category Site of action Mechanism Example 
Various physicochemical 
mechanisms 
Extra-cellular Acid binding Aluminium hydroxide 
Targets of monoclonal 
antibodies 
Cell surface Immunoglobulin E (IgE) Omalizumab 
Transport proteins Cell surface Inhibitors of Na+/K+ 
ATPase 
Digoxin 
Ionic channels Cell surface Inhibitor of Epithelial 
Na+ channels (ENaC) 
Amiloride 
Receptors Cell surface Agonist of vasopressin 
receptor 
Vasopressin 
Cytoplasmic Glucocorticoid receptors Glucocorticoids 
Intra-nuclear Thyroid hormone 
receptors 
Thyroxine 





Cytoplasmic Asparagine Asparaginase 
DNA/RNA and ribosomes Cytoplasmic and 
Intra-nuclear 
Interaction with r-RNA Aminoglycosides 
Unknown mechanism of 
action 
- - Ambroxol 
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